Literature DB >> 25177033

Blockade of HERG human K+ channels by the antidepressant drug paroxetine.

Seung Ho Lee1, Min Ji Sung, Hyang Mi Lee, Daehyun Chu, Sang June Hahn, Su-Hyun Jo, Han Choe, Bok Hee Choi.   

Abstract

The effects of paroxetine, a selective serotonin reuptake inhibitor, on human ether-a-go-go-related gene (HERG) channels were investigated using the whole-cell patch-clamp technique. The HERG channels were stably expressed in human embryonic kidney cells. Paroxetine inhibited the peak tail currents of the HERG channel in a concentration-dependent manner, with an IC50 value of 0.45 µM and a Hill coefficient of 0.85. These effects were reversible after wash-out of the drug. The paroxetine-induced inhibition of the HERG channels was voltage-dependent. There was a steep increase in inhibition over the voltage range of the channel opening. Also, a shallow voltage-dependent inhibition was detected over the voltage range in which the channels were fully activated. The fractional electrical distance was estimated to be 0.11. Paroxetine induced a leftward shift in the voltage-dependence of the steady-state activation of the HERG channels. Before and after application of the 1 µM paroxetine, the half-maximum activation was -14.21 mV and -27.04 mV, respectively, with no shift in the slope value. The HERG channel block was not use-dependent. The characteristics of the block were dependent on open and inactivated channel states rather than closed state. Paroxetine had no effect on activation and deactivation kinetics, steady-state inactivation. These results suggest that paroxetine blocks the HERG channels by binding to these channels in the open and inactivated states.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25177033     DOI: 10.1248/bpb.b14-00244

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  9 in total

1.  Comparative Cardiac Safety of Selective Serotonin Reuptake Inhibitors among Individuals Receiving Maintenance Hemodialysis.

Authors:  Magdalene M Assimon; M Alan Brookhart; Jennifer E Flythe
Journal:  J Am Soc Nephrol       Date:  2019-03-18       Impact factor: 10.121

2.  The Synergistic Combination of Everolimus and Paroxetine Exerts Post-ischemic Neuroprotection In Vitro.

Authors:  V S Suvanish Kumar; Etheresia Pretorius; G K Rajanikant
Journal:  Cell Mol Neurobiol       Date:  2018-07-30       Impact factor: 5.046

3.  Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.

Authors:  Nevena M Maljuric; Raymond Noordam; Nikkie Aarts; Maartje N Niemeijer; Marten E van den Berg; Albert Hofman; Jan A Kors; Bruno H Stricker; Loes E Visser
Journal:  Br J Clin Pharmacol       Date:  2015-07-29       Impact factor: 4.335

4.  Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study.

Authors:  Bengt Danielsson; Julius Collin; Gudrun Jonasdottir Bergman; Natalia Borg; Peter Salmi; Johan Fastbom
Journal:  Br J Clin Pharmacol       Date:  2016-01-11       Impact factor: 4.335

Review 5.  The Role of Interaction Model in Simulation of Drug Interactions and QT Prolongation.

Authors:  Barbara Wiśniowska; Sebastian Polak
Journal:  Curr Pharmacol Rep       Date:  2016-10-27

6.  Paroxetine-induced QTc prolongation.

Authors:  Yuji Otsuka
Journal:  J Gen Fam Med       Date:  2017-09-25

7.  Mitragynine, an euphoric compound inhibits hERG1a/1b channel current and upregulates the complexation of hERG1a-Hsp90 in HEK293-hERG1a/1b cells.

Authors:  Yea Lu Tay; Azimah Amanah; Mohd Ilham Adenan; Habibah Abdul Wahab; Mei Lan Tan
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

8.  Blockade of Kv1.5 by paroxetine, an antidepressant drug.

Authors:  Hyang Mi Lee; Sang June Hahn; Bok Hee Choi
Journal:  Korean J Physiol Pharmacol       Date:  2015-12-31       Impact factor: 2.016

9.  Structural implications of hERG K+ channel block by a high-affinity minimally structured blocker.

Authors:  Matthew V Helliwell; Yihong Zhang; Aziza El Harchi; Chunyun Du; Jules C Hancox; Christopher E Dempsey
Journal:  J Biol Chem       Date:  2018-03-15       Impact factor: 5.157

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.